Abivax (ABVX) analyst forecast and price target
Analyst forecast
Consensus of 18 analyst ratings
Based on 8 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Piper Sandler | Maintained | Overweight | $175.00 from $165.00 | Jul 9, 2026 |
| Truist Securities | Maintained | Buy | $155.00 from $135.00 | Jul 2, 2026 |
| Citizens | Maintained | Market Outperform | $187.00 | Jul 1, 2026 |
| BTIG | Maintained | Buy | $175.00 from $150.00 | Jun 30, 2026 |
| Wedbush | Maintained | Neutral | $110.00 from $90.00 | Jun 30, 2026 |
| Leerink Partners | Maintained | Outperform | $148.00 from $140.00 | Jun 30, 2026 |
| Jefferies | Upgraded | Hold → Buy | $158.00 from $108.00 | Jun 30, 2026 |
| BTIG | Maintained | Buy | $150.00 | Jun 16, 2026 |
| BTIG | Maintained | Buy | $150.00 | Jun 2, 2026 |
| Wedbush | Upgraded | Underperform → Neutral | $90.00 from $110.00 | Jun 2, 2026 |
| Morgan Stanley | Maintained | Overweight | $132.00 from $145.00 | Jun 2, 2026 |
| Jefferies | Downgraded | Buy → Hold | $90.00 from $160.00 | Jun 2, 2026 |
| Citizens | Maintained | Market Outperform | $187.00 from $131.00 | Jun 2, 2026 |
| Truist Securities | Maintained | Buy | $135.00 from $140.00 | Jun 2, 2026 |
| Citizens | Maintained | Market Outperform | $131.00 | May 26, 2026 |
| Barclays | Maintained | Overweight | $148.00 from $142.00 | Mar 24, 2026 |
| Jefferies | Initiated Coverage | Buy | $160.00 | Mar 16, 2026 |
| BTIG | Maintained | Buy | $150.00 | Feb 25, 2026 |
| Wedbush | Initiated Coverage | Underperform | $110.00 | Feb 24, 2026 |
| Morgan Stanley | Maintained | Overweight | $145.00 from $101.00 | Jan 9, 2026 |
Frequently asked questions
What is the price target for ABVX stock?
The average 12-month analyst price target for Abivax (ABVX) is $155.00, with a high estimate of $187.00 and a low of $110.00, across 8 analysts.
Is ABVX a buy, sell, or hold?
Analysts covering Abivax currently average a Buy rating: 16 buy, 2 hold and 0 sell, from 18 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ABVX?
The average price target of $155.00 implies 38.17% upside from the last price of $112.18.
What is the latest analyst rating on ABVX?
On Jul 9, 2026, Piper Sandler maintained Abivax at Overweight with a price target of $175.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.